Senzer's pharmaceutical cannabinoid device has won another major design award, with the German Design Council commending the unique inhaler for having 'a clear modern design that perfectly combines ergonomics and functionality'.  Â
First-to-market cannabinoid drug developer GW Pharmaceuticals (Nasdaq: GWPH) has announced that it intends to sell $300 million of American Depository Shares.
Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced top line results from a Phase 1 clinical program studying ZYN001, the Company’s patent-protected, pro-drug of tetrahydrocannabinol (THC) delivered via a transdermal patch, in healthy volunteers.